Stock Analysis

Samhwa Crown & Closure Third Quarter 2024 Earnings: EPS: ₩1,049 (vs ₩5,226 loss in 3Q 2023)

KOSE:A004450
Source: Shutterstock

Samhwa Crown & Closure (KRX:004450) Third Quarter 2024 Results

Key Financial Results

  • Revenue: ₩43.6b (up 9.7% from 3Q 2023).
  • Net income: ₩1.89b (up from ₩9.48b loss in 3Q 2023).
  • Profit margin: 4.3% (up from net loss in 3Q 2023). The move to profitability was primarily driven by lower expenses.
  • EPS: ₩1,049 (up from ₩5,226 loss in 3Q 2023).
earnings-and-revenue-history
KOSE:A004450 Earnings and Revenue History November 20th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Samhwa Crown & Closure shares are up 1.2% from a week ago.

Risk Analysis

Be aware that Samhwa Crown & Closure is showing 3 warning signs in our investment analysis that you should know about...

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KOSE:A004450

Samhwa Crown & Closure

Manufactures and sells bottle caps used in the packaging of beverages, alcohol, and food in South Korea and internationally.

Good value with adequate balance sheet and pays a dividend.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor